{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T20:59:46Z","timestamp":1791665986131,"version":"4.3.4"},"reference-count":60,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,8,20]],"date-time":"2024-08-20T00:00:00Z","timestamp":1724112000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,8,20]],"date-time":"2024-08-20T00:00:00Z","timestamp":1724112000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurosurg Rev"],"DOI":"10.1007\/s10143-024-02667-8","type":"journal-article","created":{"date-parts":[[2024,8,20]],"date-time":"2024-08-20T10:02:06Z","timestamp":1724148126000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Is add-on Bevacizumab therapy to Temozolomide and radiotherapy associated with clinical utility for newly diagnosed Glioblastoma? A systematic review and meta-analysis"],"prefix":"10.1007","volume":"47","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7600-6925","authenticated-orcid":false,"given":"Mohammad Amin","family":"Habibi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-7407-1965","authenticated-orcid":false,"given":"Niloufar","family":"Shad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-7553-1016","authenticated-orcid":false,"given":"Mohammad Sina","family":"Mirjnani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-9886-446X","authenticated-orcid":false,"given":"Sara","family":"Fasihi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0138-1872","authenticated-orcid":false,"given":"Sara","family":"Sadeghi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-6372-4994","authenticated-orcid":false,"given":"Shaghayegh","family":"Karami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad Hussain","family":"Ahmadvand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-6964-8101","authenticated-orcid":false,"given":"Pouria","family":"Delbari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-1654-6741","authenticated-orcid":false,"given":"Amir Hossein","family":"Zare","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amir Hessam","family":"Zare","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seyed Ahmad Naseri","family":"Alavi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,8,20]]},"reference":[{"issue":"9","key":"2667_CR1","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1038\/ncpneuro0289","volume":"2","author":"JA Schwartzbaum","year":"2006","unstructured":"Schwartzbaum JA et al (2006) Epidemiology and molecular pathology of glioma. Nat Clin Pract Neurol 2(9):494\u2013503 quiz 1 p following 516","journal-title":"Nat Clin Pract Neurol"},{"issue":"1","key":"2667_CR2","first-page":"3","volume":"18","author":"F Hanif","year":"2017","unstructured":"Hanif F et al (2017) Glioblastoma Multiforme: a review of its epidemiology and Pathogenesis through clinical presentation and treatment. Asian Pac J Cancer Prev 18(1):3\u20139","journal-title":"Asian Pac J Cancer Prev"},{"key":"2667_CR3","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/j.jconrel.2022.09.065","volume":"352","author":"T Li","year":"2022","unstructured":"Li T et al (2022) Glioma diagnosis and therapy: current challenges and nanomaterial-based solutions. J Control Release 352:338\u2013370","journal-title":"J Control Release"},{"issue":"1","key":"2667_CR4","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/s40001-023-01011-y","volume":"28","author":"N Salari","year":"2023","unstructured":"Salari N et al (2023) The global prevalence of primary central nervous system tumors: a systematic review and meta-analysis. Eur J Med Res 28(1):39","journal-title":"Eur J Med Res"},{"key":"2667_CR5","doi-asserted-by":"crossref","unstructured":"Darvishi M et al (2024) P104: a single-center perspective on glioma epidemiology from 2018\u20132023 in the Middle East. Genet Med Open, 2","DOI":"10.1016\/j.gimo.2024.100985"},{"issue":"3","key":"2667_CR6","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1007\/s11060-018-03015-9","volume":"140","author":"IJ-K M","year":"2018","unstructured":"M IJ-K et al (2018) Prevalence of symptoms in glioma patients throughout the disease trajectory: a systematic review. J Neurooncol 140(3):485\u2013496","journal-title":"J Neurooncol"},{"key":"2667_CR7","unstructured":"Tamimi AF, Juweid M (2017) Epidemiology and Outcome of Glioblastoma, in Glioblastoma, S. De Vleeschouwer, Editor. Codon Publications Copyright: The Authors.: Brisbane (AU)"},{"issue":"3","key":"2667_CR8","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1093\/jnen\/61.3.215","volume":"61","author":"P Kleihues","year":"2002","unstructured":"Kleihues P et al (2002) The WHO classification of tumors of the nervous system. J Neuropathology Experimental Neurol 61(3):215\u2013225","journal-title":"J Neuropathology Experimental Neurol"},{"issue":"5","key":"2667_CR9","first-page":"669","volume":"29","author":"M Kochi","year":"2002","unstructured":"Kochi M, Ushio Y (2002) Chemo-radiotherapy for malignant brain tumors. Gan Kagaku Ryoho 29(5):669\u2013676","journal-title":"Gan Kagaku Ryoho"},{"issue":"1","key":"2667_CR10","first-page":"11","volume":"13","author":"S Kobayashi","year":"1986","unstructured":"Kobayashi S, Takakura K (1986) Treatment modalities for malignant gliomas with reference to their pathophysiology]. Gan Kagaku Ryoho 13(1):11\u201317","journal-title":"Gan Kagaku Ryoho"},{"issue":"10","key":"2667_CR11","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJMoa043330","volume":"352","author":"R Stupp","year":"2005","unstructured":"Stupp R et al (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352(10):987\u2013996","journal-title":"N Engl J Med"},{"issue":"3","key":"2667_CR12","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.semradonc.2009.02.004","volume":"19","author":"MH Barcellos-Hoff","year":"2009","unstructured":"Barcellos-Hoff MH et al (2009) Therapeutic targets in malignant glioblastoma microenvironment. Semin Radiat Oncol 19(3):163\u2013170","journal-title":"Semin Radiat Oncol"},{"key":"2667_CR13","doi-asserted-by":"crossref","first-page":"102017","DOI":"10.1016\/j.ctrv.2020.102017","volume":"86","author":"J Garcia","year":"2020","unstructured":"Garcia J et al (2020) Bevacizumab (Avastin\u00ae) in cancer treatment: a review of 15 years of clinical experience and future outlook. Cancer Treat Rev 86:102017","journal-title":"Cancer Treat Rev"},{"issue":"8","key":"2667_CR14","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1212\/01.wnl.0000208958.29600.87","volume":"66","author":"WB Pope","year":"2006","unstructured":"Pope WB et al (2006) MRI in patients with high-grade gliomas treated with bevacizumab and chemotherapy. Neurology 66(8):1258\u20131260","journal-title":"Neurology"},{"issue":"11","key":"2667_CR15","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1038\/nrneurol.2009.159","volume":"5","author":"AD Norden","year":"2009","unstructured":"Norden AD, Drappatz J, Wen PY (2009) Antiangiogenic therapies for high-grade glioma. Nat Rev Neurol 5(11):610\u2013620","journal-title":"Nat Rev Neurol"},{"issue":"30","key":"2667_CR16","doi-asserted-by":"crossref","first-page":"4722","DOI":"10.1200\/JCO.2007.12.2440","volume":"25","author":"JJ Vredenburgh","year":"2007","unstructured":"Vredenburgh JJ et al (2007) Bevacizumab plus Irinotecan in recurrent glioblastoma multiforme. J Clin Oncol 25(30):4722\u20134729","journal-title":"J Clin Oncol"},{"issue":"7","key":"2667_CR17","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1007\/s00701-021-04794-3","volume":"163","author":"DP Kulinich","year":"2021","unstructured":"Kulinich DP et al (2021) Radiotherapy versus combination radiotherapy-bevacizumab for the treatment of recurrent high-grade glioma: a systematic review. Acta Neurochir (Wien) 163(7):1921\u20131934","journal-title":"Acta Neurochir (Wien)"},{"key":"2667_CR18","first-page":"n71","volume":"372","author":"JP Matthew","year":"2021","unstructured":"Matthew JP et al (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 372:n71","journal-title":"BMJ"},{"key":"2667_CR19","doi-asserted-by":"crossref","unstructured":"Deeks JJ et al (2019) Analysing data and undertaking meta-analyses, in Cochrane Handbook for Systematic Reviews of Interventions. pp. 241\u2013284","DOI":"10.1002\/9781119536604.ch10"},{"key":"2667_CR20","doi-asserted-by":"crossref","unstructured":"Carlson JA et al (2015) Hypofractionated-intensity modulated radiotherapy (hypo-IMRT) and temozolomide (TMZ) with or without bevacizumab (BEV) for newly diagnosed glioblastoma multiforme (GBM): a comparison of two prospective phase II trials, vol 123. JOURNAL OF NEURO-ONCOLOGY, pp 251\u2013257. 2","DOI":"10.1007\/s11060-015-1791-4"},{"issue":"7","key":"2667_CR21","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1093\/annonc\/mdu148","volume":"25","author":"B Chauffert","year":"2014","unstructured":"Chauffert B et al (2014) Randomized phase II trial of irinotecan and bevacizumab as neo-adjuvant and adjuvant to temozolomide-based chemoradiation compared with temozolomide-chemoradiation for unresectable glioblastoma: final results of the TEMAVIR study from ANOCEF\u2020. Ann Oncol 25(7):1442\u20131447","journal-title":"Ann Oncol"},{"issue":"4","key":"2667_CR22","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1007\/s12325-011-0007-3","volume":"28","author":"OL Chinot","year":"2011","unstructured":"Chinot OL et al (2011) AVAglio: phase 3 trial of bevacizumab plus temozolomide and radiotherapy in newly diagnosed glioblastoma multiforme. Adv Ther 28(4):334\u2013340","journal-title":"Adv Ther"},{"issue":"8","key":"2667_CR23","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.7150\/jca.18339","volume":"8","author":"I Darmon","year":"2017","unstructured":"Darmon I et al (2017) Temozolomide and Bevacizumab Induction before Chemoradiotherapy in patients with bulky glioblastoma and\/or with severe neurological impairment. J Cancer 8(8):1417\u20131424","journal-title":"J Cancer"},{"issue":"8","key":"2667_CR24","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1056\/NEJMoa1308573","volume":"370","author":"MR Gilbert","year":"2014","unstructured":"Gilbert MR et al (2014) A randomized trial of bevacizumab for newly diagnosed glioblastoma. N Engl J Med 370(8):699\u2013708","journal-title":"N Engl J Med"},{"key":"2667_CR25","doi-asserted-by":"crossref","unstructured":"Grill J et al (2018) Phase II, Open-Label, Randomized, Multicenter Trial (HERBY) of Bevacizumab in Pediatric patients with newly diagnosed high-Grade Glioma, vol 36. JOURNAL OF CLINICAL ONCOLOGY, pp 951\u2013. 10","DOI":"10.1200\/JCO.2017.76.0611"},{"issue":"4","key":"2667_CR26","first-page":"240","volume":"10","author":"JD Hainsworth","year":"2012","unstructured":"Hainsworth JD et al (2012) Phase II study of concurrent radiation therapy, temozolomide, and bevacizumab followed by bevacizumab\/everolimus as first-line treatment for patients with glioblastoma. Clin Adv Hematol Oncol 10(4):240\u2013246","journal-title":"Clin Adv Hematol Oncol"},{"issue":"5","key":"2667_CR27","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1016\/j.ijrobp.2007.11.068","volume":"71","author":"A Lai","year":"2008","unstructured":"Lai A et al (2008) Phase II pilot study of bevacizumab in combination with temozolomide and regional radiation therapy for up-front treatment of patients with newly diagnosed glioblastoma multiforme: interim analysis of safety and tolerability. Int J Radiat Oncol Biol Phys 71(5):1372\u20131380","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"2","key":"2667_CR28","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1200\/JCO.2010.30.2729","volume":"29","author":"A Lai","year":"2011","unstructured":"Lai A et al (2011) Phase II study of bevacizumab plus temozolomide during and after radiation therapy for patients with newly diagnosed glioblastoma multiforme. J Clin Oncol 29(2):142\u2013148","journal-title":"J Clin Oncol"},{"key":"2667_CR29","doi-asserted-by":"crossref","unstructured":"Li L et al (2022) Potential F-18-RGD PET\/CT and DCE-MRI imaging-based biomarkers for postoperative survival prediction among patients with newly diagnosed glioblastoma treated with Bevacizumab and Chemoradiotherapy. FRONTIERS IN ONCOLOGY, p 12","DOI":"10.3389\/fonc.2022.848266"},{"key":"2667_CR30","doi-asserted-by":"crossref","unstructured":"Nagane M et al (2022) Bevacizumab beyond Progression for Newly Diagnosed Glioblastoma (BIOMARK): Phase II Safety, Efficacy and Biomarker Study CANCERS, 14(22)","DOI":"10.3390\/cancers14225522"},{"issue":"2","key":"2667_CR31","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.ijrobp.2008.05.062","volume":"72","author":"A Narayana","year":"2008","unstructured":"Narayana A et al (2008) Feasibility of using bevacizumab with radiation therapy and temozolomide in newly diagnosed high-grade glioma. Int J Radiat Oncol Biol Phys 72(2):383\u2013389","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"2","key":"2667_CR32","doi-asserted-by":"crossref","first-page":"341","DOI":"10.3171\/2011.9.JNS11656","volume":"116","author":"A Narayana","year":"2012","unstructured":"Narayana A et al (2012) A clinical trial of bevacizumab, temozolomide, and radiation for newly diagnosed glioblastoma. J Neurosurg 116(2):341\u2013345","journal-title":"J Neurosurg"},{"key":"2667_CR33","doi-asserted-by":"crossref","unstructured":"Ney DE et al (2015) Phase II trial of hypofractionated intensity-modulated radiation therapy combined with temozolomide and bevacizumab for patients with newly diagnosed glioblastoma, vol 122. JOURNAL OF NEURO-ONCOLOGY, pp 135\u2013143. 1","DOI":"10.1007\/s11060-014-1691-z"},{"key":"2667_CR34","doi-asserted-by":"crossref","unstructured":"Omuro A et al (2014) Phase II study of Bevacizumab, Temozolomide, and Hypofractionated Stereotactic Radiotherapy for newly diagnosed Glioblastoma, vol 20. CLINICAL CANCER RESEARCH, pp 5023\u20135031. 19","DOI":"10.1158\/1078-0432.CCR-14-0822"},{"issue":"25","key":"2667_CR35","doi-asserted-by":"crossref","first-page":"2735","DOI":"10.1200\/JCO.2015.61.5005","volume":"33","author":"T Sandmann","year":"2015","unstructured":"Sandmann T et al (2015) Patients with Proneural Glioblastoma May derive overall Survival Benefit from the addition of Bevacizumab to First-Line Radiotherapy and Temozolomide: retrospective analysis of the AVAglio Trial. J Clin Oncol 33(25):2735\u20132744","journal-title":"J Clin Oncol"},{"issue":"7","key":"2667_CR36","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1093\/neuonc\/nov300","volume":"18","author":"F Saran","year":"2016","unstructured":"Saran F et al (2016) Bevacizumab, temozolomide, and radiotherapy for newly diagnosed glioblastoma: comprehensive safety results during and after first-line therapy. Neuro Oncol 18(7):991\u20131001","journal-title":"Neuro Oncol"},{"key":"2667_CR37","doi-asserted-by":"crossref","unstructured":"Shih KC et al (2010) Phase II trial of radiation therapy\/temozolomide\/bevacizumab followed by bevacizumab\/everolimus in the first- line treatment of glioblastoma multiforme (GBM), vol 28. JOURNAL OF CLINICAL ONCOLOGY, 15","DOI":"10.1200\/jco.2010.28.15_suppl.2075"},{"issue":"19","key":"2667_CR38","doi-asserted-by":"crossref","first-page":"2166","DOI":"10.1200\/JCO.2014.60.3217","volume":"33","author":"MJ Taphoorn","year":"2015","unstructured":"Taphoorn MJ et al (2015) Health-Related Quality of Life in a Randomized Phase III Study of Bevacizumab, Temozolomide, and Radiotherapy in newly diagnosed Glioblastoma. J Clin Oncol 33(19):2166\u20132175","journal-title":"J Clin Oncol"},{"issue":"2","key":"2667_CR39","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1634\/theoncologist.2014-0418","volume":"20","author":"ME van Linde","year":"2015","unstructured":"van Linde ME et al (2015) Bevacizumab in Combination with Radiotherapy and Temozolomide for PatientsWith newly diagnosed Glioblastoma Multiforme. ONCOLOGIST 20(2):107\u2013108","journal-title":"ONCOLOGIST"},{"key":"2667_CR40","doi-asserted-by":"crossref","unstructured":"Vredenburgh JJ et al (2011) The addition of Bevacizumab to Standard Radiation Therapy and Temozolomide followed by Bevacizumab, Temozolomide, and Irinotecan for newly diagnosed Glioblastoma, vol 17. CLINICAL CANCER RESEARCH, pp 4119\u20134124. 12","DOI":"10.1158\/1078-0432.CCR-11-0120"},{"issue":"10","key":"2667_CR41","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1093\/neuonc\/now091","volume":"18","author":"W Wick","year":"2016","unstructured":"Wick W et al (2016) Evaluation of pseudoprogression rates and tumor progression patterns in a phase III trial of bevacizumab plus radiotherapy\/temozolomide for newly diagnosed glioblastoma. Neuro Oncol 18(10):1434\u20131441","journal-title":"Neuro Oncol"},{"key":"2667_CR42","doi-asserted-by":"crossref","unstructured":"Gruber ML et al (2009) Bevacizumab in combination with radiotherapy plus concomitant and adjuvant temozolomide for newly diagnosed glioblastoma: update progression-free survival, overall survival, and toxicity, vol 27. JOURNAL OF CLINICAL ONCOLOGY, 15","DOI":"10.1200\/jco.2009.27.15_suppl.2017"},{"key":"2667_CR43","doi-asserted-by":"crossref","unstructured":"Chinot OL et al (2011) AVAglio: phase 3 trial of Bevacizumab Plus Temozolomide and Radiotherapy in newly diagnosed Glioblastoma Multiforme, vol 28. ADVANCES IN THERAPY, pp 334\u2013340. 4","DOI":"10.1007\/s12325-011-0007-3"},{"key":"2667_CR44","doi-asserted-by":"crossref","unstructured":"Friedman HS et al (2012) The addition of bevacizumab to temozolomide and radiation therapy followed by bevacizumab, temozolomide, and oral topotecan for newly diagnosed glioblastoma multiforme (GBM), vol 30. JOURNAL OF CLINICAL ONCOLOGY, 15","DOI":"10.1200\/jco.2012.30.15_suppl.2090"},{"key":"2667_CR45","doi-asserted-by":"crossref","first-page":"429","DOI":"10.2147\/OTT.S125587","volume":"10","author":"N Hata","year":"2017","unstructured":"Hata N et al (2017) Add-on bevacizumab can prevent early clinical deterioration and prolong survival in newly diagnosed partially resected glioblastoma patients with a poor performance status. Onco Targets Ther 10:429\u2013437","journal-title":"Onco Targets Ther"},{"key":"2667_CR46","doi-asserted-by":"crossref","unstructured":"Taphoorn MJB et al (2015) Health-Related Quality of Life in a Randomized Phase III Study of Bevacizumab, Temozolomide, and Radiotherapy in newly diagnosed Glioblastoma, vol 33. JOURNAL OF CLINICAL ONCOLOGY, pp 2166\u2013. 19","DOI":"10.1200\/JCO.2014.60.3217"},{"issue":"10","key":"2667_CR47","first-page":"1434","volume":"18","author":"W Wick","year":"2016","unstructured":"Wick W et al (2016) Evaluation of pseudoprogression rates and tumor progression patterns in a phase III trial of bevacizumab plus radiotherapy\/temozolomide for newly diagnosed glioblastoma. Neurooncology 18(10):1434\u20131441","journal-title":"Neurooncology"},{"key":"2667_CR48","doi-asserted-by":"crossref","unstructured":"Vredenburgh JJ et al (2012) ADDITION OF BEVACIZUMAB TO STANDARD RADIATION THERAPY AND DAILY TEMOZOLOMIDE IS ASSOCIATED WITH MINIMAL TOXICITY IN NEWLY DIAGNOSED GLIOBLASTOMA MULTIFORME, vol 82. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, pp 58\u201366. 1","DOI":"10.1016\/j.ijrobp.2010.08.058"},{"key":"2667_CR49","doi-asserted-by":"crossref","unstructured":"Hart MG et al (2013) Temozolomide for high grade glioma. Cochrane Database Syst Rev, 2013(4): p. Cd007415.","DOI":"10.1002\/14651858.CD007415.pub2"},{"key":"2667_CR50","doi-asserted-by":"crossref","first-page":"966696","DOI":"10.3389\/fimmu.2023.966696","volume":"14","author":"B Guo","year":"2023","unstructured":"Guo B et al (2023) Efficacy and safety of innate and adaptive immunotherapy combined with standard of care in high-grade gliomas: a systematic review and meta-analysis. Front Immunol 14:966696","journal-title":"Front Immunol"},{"issue":"9","key":"2667_CR51","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1007\/s11547-021-01381-5","volume":"126","author":"B Detti","year":"2021","unstructured":"Detti B et al (2021) Bevacizumab in recurrent high-grade glioma: a single institution retrospective analysis on 92 patients. Radiol Med 126(9):1249\u20131254","journal-title":"Radiol Med"},{"issue":"3","key":"2667_CR52","doi-asserted-by":"crossref","first-page":"452","DOI":"10.3892\/etm.2023.12151","volume":"26","author":"G Li","year":"2023","unstructured":"Li G et al (2023) Efficacy of apatinib combined with temozolomide in the treatment of recurrent high\u2013grade glioma: a meta\u2013analysis. Exp Ther Med 26(3):452","journal-title":"Exp Ther Med"},{"issue":"5","key":"2667_CR53","doi-asserted-by":"crossref","first-page":"833","DOI":"10.3892\/mco.2016.816","volume":"4","author":"P Fu","year":"2016","unstructured":"Fu P et al (2016) Bevacizumab treatment for newly diagnosed glioblastoma: systematic review and meta-analysis of clinical trials. Mol Clin Oncol 4(5):833\u2013838","journal-title":"Mol Clin Oncol"},{"key":"2667_CR54","doi-asserted-by":"crossref","unstructured":"Ameratunga M et al (2018) Anti-angiogenic therapy for high-grade glioma. Cochrane Database Syst Rev, 11(11): p. Cd008218.","DOI":"10.1002\/14651858.CD008218.pub4"},{"key":"2667_CR55","doi-asserted-by":"crossref","unstructured":"Khasraw M et al Antiangiogenic therapy for high-grade glioma. Cochrane Database Syst Rev, 2014(9): p. Cd008218.","DOI":"10.1002\/14651858.CD008218.pub3"},{"key":"2667_CR56","doi-asserted-by":"crossref","first-page":"e236","DOI":"10.1016\/j.wneu.2019.06.043","volume":"130","author":"J Dong","year":"2019","unstructured":"Dong J et al (2019) Risk of adverse vascular events in patients with malignant glioma treated with Bevacizumab Plus Irinotecan: a systematic review and Meta-analysis. World Neurosurg 130:e236\u2013e243","journal-title":"World Neurosurg"},{"issue":"2","key":"2667_CR57","first-page":"174","volume":"27","author":"W Wang","year":"2017","unstructured":"Wang W et al (2017) Chemotherapy for adults with malignant glioma: a systematic review and network Meta-analysis. Turk Neurosurg 27(2):174\u2013181","journal-title":"Turk Neurosurg"},{"issue":"42","key":"2667_CR58","doi-asserted-by":"crossref","first-page":"69002","DOI":"10.18632\/oncotarget.10763","volume":"7","author":"L Qi","year":"2016","unstructured":"Qi L et al (2016) A network meta-analysis: the overall and progression-free survival of glioma patients treated by different chemotherapeutic interventions combined with radiation therapy (RT). Oncotarget 7(42):69002\u201369013","journal-title":"Oncotarget"},{"issue":"1","key":"2667_CR59","doi-asserted-by":"crossref","first-page":"e59","DOI":"10.1200\/JOP.2012.000560","volume":"11","author":"JJ Raizer","year":"2015","unstructured":"Raizer JJ et al (2015) Economics of malignant gliomas: a critical review. J Oncol Pract 11(1):e59\u201365","journal-title":"J Oncol Pract"},{"issue":"2","key":"2667_CR60","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1007\/s11060-020-03451-6","volume":"147","author":"L Marenco-Hillembrand","year":"2020","unstructured":"Marenco-Hillembrand L et al (2020) Trends in glioblastoma: outcomes over time and type of intervention: a systematic evidence based analysis. J Neurooncol 147(2):297\u2013307","journal-title":"J Neurooncol"}],"container-title":["Neurosurgical Review"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10143-024-02667-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10143-024-02667-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10143-024-02667-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,4]],"date-time":"2025-03-04T10:41:15Z","timestamp":1741084875000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10143-024-02667-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,20]]},"references-count":60,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["2667"],"URL":"https:\/\/doi.org\/10.1007\/s10143-024-02667-8","relation":{},"ISSN":["1437-2320"],"issn-type":[{"value":"1437-2320","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,20]]},"assertion":[{"value":"22 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 August 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 August 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 August 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study is deemed to exempt to received ethical approval.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"445"}}